Evidence map›Paper›PMID 41644104›Full record

ArticleBrain pathology (Zurich, Switzerland)2026

TrkA abundance is increased in cutaneous nerves in bortezomib-induced neuropathy.

Yuying Jin, Nadine Cebulla, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser and 5 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuying JinDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0009-0009-6397-9539
Nadine CebullaDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0002-2376-2281
Daniel SchirmerDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Eva RunauDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Leon FlammDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Calvin TerhorstDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Laura JähnelDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Johanna GüseDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Nicola GiordaniDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Annett WieserDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Julian BrenneckeDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Annemarie SodmannDepartment of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, Centre for Interdisciplinary Pain Medicine, University Hospital of Würzburg, Würzburg, Germany.
Martin KortümDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Robert BlumDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.
Claudia SommerDepartment of Neurology, University Hospital of Würzburg, Würzburg, Germany.ORCID https://orcid.org/0000-0002-7064-5002

Funding

China Scholarship Council (CSC) 202106230110Deutsche Forschungsgemeinschaft 426503586
6 · The paper itself

Abstract

Tropomyosin receptor kinase A (TrkA), a high-affinity receptor for nerve growth factor (NGF), is implicated in nociception and local angiogenesis. We investigated TrkA localization and abundance in skin biopsies from multiple myeloma patients who developed peripheral neuropathy during bortezomib treatment. We recruited 50 multiple myeloma patients with bortezomib-induced peripheral neuropathy (BIPN), including 31 without pain and 19 with pain, and 27 matched healthy controls at University Hospital Würzburg (2021-2024). Skin biopsies from the distal leg were analyzed to determine intraepidermal nerve fiber density (IENFD) and area, TrkA mean fluorescence intensity (MFI) and gene expression levels. Additionally, the area of blood vessels and proximity to nerves was measured. BIPN patients exhibited significant sensory abnormalities, decreased IENFD, and increased TrkA protein abundance in surviving epidermal nerve fibers, correlating with cycles of bortezomib treatment. No substantial difference in TrkA gene expression was observed between groups. All BIPN patients demonstrated increased dermal vascularization compared with control, and only those without pain showed increased nerve-vessel interactions. These results suggest a strong association between dysregulated TrkA signaling and altered neurovascular interactions with small fiber pathology in BIPN.

Indexed as

Antineoplastic AgentsBortezomibPeripheral Nervous System DiseasesReceptor, trkASkinAgedFemaleHumansMaleMiddle AgedMultiple MyelomaNerve FibersAntineoplastic AgentsBortezomibNTRK1 protein, humanReceptor, trkAchemotherapy‐induced neuropathydeep learning‐based quantitative analysismolecular biomarker

Identifiers

PMID41644104
PMCPMC13238710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.